Lightnews — Scholar-powered news

Kapil Meleveedu

@hematologymd.bsky.social

1.7K followers 1.3K following 33 posts

Asst Prof, Director Transplant and Cell Therapy, Malignant hematology head. Physician entrepreneur. Interested in Stem cells, myeloid and all things 🩸. You will find me around animals, nature, fun and real life stories. Anti-bot.

Posts Media Videos Starter Packs

Pinned

Kapil Meleveedu @hematologymd.bsky.social · Dec 21

A team that is incredibly passionate and tireless.A leadership that’s phenomenal and visionary. United in a common mission to offer hope and bring smiles.A success story of possibilities and resilience on the anniversary of our new BMT program and honored to lead it!

today.uconn.edu/2024/12/bone...

Bone Marrow Transplant Team Provides Lifesaving Care for German Patient with Rare Brain Cancer - UConn Today

As the couple prepares to head back to Germany, they say they will always consider UConn Health their second home

today.uconn.edu

1 4

Kapil Meleveedu @hematologymd.bsky.social · Aug 15

Four fold increase in risk of infectious complications after stem cell transplant with oral mucositis than without.
www.mdpi.com/2072-6694/17...

www.mdpi.com

Kapil Meleveedu @hematologymd.bsky.social · May 17

www.nejm.org/doi/full/10....

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM

Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.

www.nejm.org

Kapil Meleveedu @hematologymd.bsky.social · May 9

www.nejm.org/doi/full/10....

Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...

www.nejm.org

Kapil Meleveedu @hematologymd.bsky.social · Feb 18

STOP CAR, ON CAR, OFF CAR, SNIP(er) and VIPER(s) and many other strategies!

www.nature.com/articles/s41...

Novel strategies to manage CAR-T cell toxicity - Nature Reviews Drug Discovery

Treatment with chimeric antigen receptor (CAR)-T cell therapies is associated with important immune-related adverse events. In this Review, the authors discuss the standard-of-care management for...

www.nature.com

Kapil Meleveedu @hematologymd.bsky.social · Feb 6

Although very rare, some brakes needed for the CARs
www.nejm.org/doi/full/10....

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

www.nejm.org

Kapil Meleveedu @hematologymd.bsky.social · Dec 21

Bone Marrow Transplant Team Provides Lifesaving Care for German Patient with Rare Brain Cancer - UConn Today

As the couple prepares to head back to Germany, they say they will always consider UConn Health their second home

today.uconn.edu

1 4

Kapil Meleveedu @hematologymd.bsky.social · Dec 14

Secondary malignancies after CAR-T

jamanetwork.com/journals/jam...

Kapil Meleveedu @hematologymd.bsky.social · Dec 8

Sun. Fog. Dusk. Dawn
Science and research
Dibble dibble dibble dopp
🩸🩸🩸

#ASHaiku #ASH24
@ash-hematology.bsky.social

1 14

Kapil Meleveedu @hematologymd.bsky.social · Dec 8

Greener looks the grass
Soil back to fertile
MRD awaits

#ASHaiku #ASH24

@ash-hematology.bsky.social

Kapil Meleveedu @hematologymd.bsky.social · Dec 7

Thanks to @ash-hematology.bsky.social for this feed to catch up #ASH24 in one place! No more FOMO for virtual attendees ✋🏽

2 6

Reposted by Kapil Meleveedu

Brian Bilston @brianbilston.bsky.social · Dec 7

Today’s poem is called ‘Needles’.

This poem, entitled 'Needles' is presented in the form of a Christmas tree. These words form the shape of the tree:

I
wrote
a poem
in the shape
of a Christmas
tree but then forgot
to water it and only a few

days
later
there

And these words are distributed around the base of my poem 'tree' as if they've fallen off it:

were
words
all
over
the carpet

20 300 1.7K

Kapil Meleveedu @hematologymd.bsky.social · Dec 6

#ASH24 educational Program 2024. Treasure trove of🩸🩸🩸updates

ashpublications.org/hematology/i...

Volume 2024 Issue 1 | Hematology, ASH Education Program | American Society of Hematology

Hematology, ASH Education Program | 2024 | 1 | November 2024

ashpublications.org

Kapil Meleveedu @hematologymd.bsky.social · Dec 6

We are hiring ! Looking for a BMT/cell therapy RN for our growing new BMT program. Check out the link - 'Join Our Team today' and scroll to page two for more details or DM me if anyone is interested.

health.uconn.edu/jobs

Jobs | UConn Health

Nursing Careers If you want to be part of a team where nurses are respected, valued, and encouraged to learn and grow, you want to be a nurse at UConn Healt ...

health.uconn.edu

1 2

Kapil Meleveedu @hematologymd.bsky.social · Dec 3

Severe aplastic anemia. ASTCT guidelines 2024

www.astctjournal.org/article/S266...

3 13

Kapil Meleveedu @hematologymd.bsky.social · Nov 28

Yet another CAR-T success story.
Obe-cel in B-ALL

www.nejm.org/doi/full/10....

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia | NEJM

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persis...

www.nejm.org

3 12

Reposted by Kapil Meleveedu

Anand Patel @anand-88-patel.bsky.social · Nov 27

An excellent review characterizing the role of imetelstat in lower-risk MDS!

ashpublications.org/blood/articl...

1 7

Kapil Meleveedu @hematologymd.bsky.social · Nov 26

✋🏽 Virtual though

Kapil Meleveedu @hematologymd.bsky.social · Nov 25

ECOG-ACRIN 4151: MCL pts in CR1 with undetectable MRD6 did not benefit from consolidative auto-HCT. Pts who remain MRD+ after induction may benefit from auto-HCT. LBA #ASH24
ash.confex.com/ash/2024/web...

Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Dise...

ash.confex.com

1 7

Kapil Meleveedu @hematologymd.bsky.social · Nov 25

bsky.app/profile/kisw...

Kyle Swanson, MD, FAANS, FCNS @kiswanson.medsky.social · Nov 19

Looking for medical professionals to follow? Just added the 6th installment *Medsky Sanguine Six*
#medsky 🩺🧪
Round 1
go.bsky.app/Qg2TA9p
Round 2
go.bsky.app/9ziyYqt
Round 3
go.bsky.app/9WQtZh6
Round 4
go.bsky.app/HRaNhEt
Round 5
go.bsky.app/DvGjDh6
Round 6
go.bsky.app/TzRhec3

Reposted by Kapil Meleveedu

Miguel Perales MD @drmiguelperales.bsky.social · Nov 22

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

1 26 42

Kapil Meleveedu @hematologymd.bsky.social · Nov 22

4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022

ashpublications.org/blood/articl...

2 10

Kapil Meleveedu @hematologymd.bsky.social · Nov 20

Ph 1 CD7 targeted CAR for R/R AML. Great CR rate (70%) in extensively treated pts. But short DoR without alloSCT. Relapse with CD7 loss

ashpublications.org/blood/articl...

Kapil Meleveedu @hematologymd.bsky.social · Nov 20

Great review on NLPHL

haematologica.org/article/down...

1 9

Kapil Meleveedu @hematologymd.bsky.social · Nov 18

Intriguing T-follicular helper (TFH) lymphomas

haematologica.org/article/view...

Kapil Meleveedu @hematologymd.bsky.social · Nov 18

Haven’t experienced that personally but can totally understand!